Figure 3 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
Year: 2025
Type: other
Abstract: APOBEC3B expression alters the evolutionary trajectory of acquired resistance to EGFR inhibitors. A, Kinetics of evolution of gefitinib resistance in PC9 cells with or without A3B expression. B, Representative dose–response curves to gefitinib for sensitive and resistant A3B-off and A3B-on PC9 cells. C, Quantification of the AUC of dose–response curves for gefitinib-sensitive and GR A3B-off and A3B-on PC9 cells. An unpaired t test was performed to determine statistical significance. **, P < 0.05; ***, P < 0.0005. D, Frequency of EGFRT790M mutation as determined by droplet digital PCR in gefitinib-sensitive and GR A3B-off and A3B-on PC9 cells. % EGFRT790M was calculated as described in “Materials and Methods”. E, Contingency tables summarizing the relationship between resistance kinetics and EGFR mutation status in A3B-off and A3B-on PC9 cells. Res, resistant.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4410565956